News | Radiopharmaceuticals and Tracers | August 20, 2015

The ITM Group Announces In-Licensing of DOTA-Zoledronate Theranostic Agent

Nuclear tracer indicated for bone targeted radionuclide therapy and diagnostics in patients with bone metastases

The ITM Group, in-licensing, DOTA-Zoledronate, theranostic agent, bone metastases, PET imaging

August 20, 2015 — The ITM Group announced that its subsidiary ITG GmbH has successfully in-licensed DOTA-Zoledronate, a next-generation theranostic agent for bone targeted radionuclide therapy and diagnostics in patients suffering from bone metastases. DOTA-Zoledronate specifically targets cancerous bone lesions and, when radiolabeled with therapeutic or diagnostic radioisotopes, has shown high potential for positron emission tomography (PET) imaging and endoradiotherapy.

In first studies DOTA-Zoledronate showed a high target to background ratio and a fast clearance pathway. Moreover, the novel bone agent is attractive for tagging of various radionuclides like the generator derived PET-radionuclide Gallium-68, therapeutic beta-emitting no-carrier-added (n.c.a) Lutetium-177 as well as the α-particle emitters Actinium-225 and Bismuth-213.

Due to its versatile properties for radiolabeling, DOTA-Zoledronate is a promising agent for the development of other future-oriented radionuclide therapy concepts for personalized nuclear oncology. Fundamental research into radiolabeled DOTA-Zoledronate conjugates has recently been conducted at the Johannes Gutenberg University Mainz led by the head of the Institute of Nuclear Chemistry, Prof. Frank Rösch.

For more information: www.itg-garching.de

Related Content

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Emerging Trends in Nuclear Medicine
Feature | Nuclear Imaging | June 04, 2018 | By Jeff Zagoudis
Nuclear imaging and its various modalities have long played an important role in the diagnosis and treatment of numer
Overlay Init